Results 11 to 20 of about 8,358 (142)

Zonisamide [PDF]

Epilepsia, 1999
Summary:Zonisamide (ZNS) is a broad‐spectrum antiepileptic drug in both animal models of epilepsy and patients with epilepsy. It is effective for both localization‐related and generalized epilepsies and appears to be particularly potent in progressive myoclonic epilepsy syndromes.
openaire   +2 more sources

Zonisamide for the Efficacy of Sleep Abnormality in Parkinson's Disease (ZEAL Study): A Protocol for Randomized Controlled Trials

Frontiers in Neurology, 2021
Background: Sleep disorders are one of the most frequent non-motor symptoms of Parkinson's disease (PD), and the efficacy of dopaminergic agents remains controversial.
Hiroshi Kataoka, Masahiro Isogawa, Takashi Inoue, Miyoko Hasebe, Ryuzo Takashima, Shu Kasama, Hitoki Nanaura, Takao Kiriyama, Masato Kasahara, Kazuma Sugie   +9 more
doaj   +1 more source

Effects of Chronic Administration of Zonisamide, an Antiepileptic Drug, on Bone Mineral Density and Their Prevention With Alfacalcidol in Growing Rats

Journal of Pharmacological Sciences, 2003
We investigated the effects of chronic administration of zonisamide, an antiepileptic agent, on bone metabolism in growing rats. Administration of zonisamide at a dose of 80 mg/kg per day, s.c.
Atsushi Takahashi, Kenji Onodera, Junzo Kamei, Shinobu Sakurada, Hisashi Shinoda, Shuichi Miyazaki, Takashi Saito, Hideaki Mayanagi   +7 more
doaj   +1 more source

Zonisamide Enhances Motor Effects of Levodopa, Not of Apomorphine, in a Rat Model of Parkinson’s Disease

Parkinson's Disease, 2018
Zonisamide is a relatively recent drug for Parkinson’s disease. Multiple hypotheses have been proposed to explain the antiparkinsonian effects of zonisamide.
Haruo Nishijima, Yasuo Miki, Shinya Ueno, Masahiko Tomiyama   +3 more
doaj   +1 more source

Design of Novel Drugs (P3TZ, H2P3TZ, M2P3TZ, H4P3TZ and M4P3TZ) Based on Zonisamide for Autism Treatment by Binding to Potassium Voltage-gated Channel Subfamily D Member 2 (Kv4.2) [PDF]

International Journal of New Chemistry, 2019
The present research article relates to the discovery of the novel drugs based on Zonisamide to treatment of autism disease. In first step, the electronic properties, reactivity and stability of the said compound are discussed. To attain these properties,
Mehdi Nabati, Vida Bodaghi-Namileh
doaj   +1 more source

Zonisamide Suppresses Pain Symptoms of Formalin-Induced Inflammatory and Streptozotocin-Induced Diabetic Neuropathy

Journal of Pharmacological Sciences, 2008
We evaluated the effects of zonisamide on inflammatory and neuropathic pain using the mouse formalin test and streptozotocin (STZ)-induced diabetic mice with a reduced withdrawal threshold to mechanical stimuli, respectively.
Mitsuo Tanabe, Takuhiro Murakami, Hideki Ono   +2 more
doaj   +1 more source

The Supraspinally Mediated Analgesic Effects of Zonisamide in Mice After Peripheral Nerve Injury Are Independent of the Descending Monoaminergic System

Journal of Pharmacological Sciences, 2007
We have previously demonstrated that the antiepileptic drug zonisamide supraspinally generates analgesic effects on thermal and mechanical hypersensitivity in mice after peripheral nerve injury.
Mitsuo Tanabe, Yuichi Takeuchi, Hideki Ono   +2 more
doaj   +1 more source

Zonisamide Increases Dopamine Turnover in the Striatum of Mice and Common Marmosets Treated With MPTP

Journal of Pharmacological Sciences, 2009
.: The effect of zonisamide, an antiepileptic agent with anti-parkinsonian effects, was studied on dopamine neurons of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 mice and common marmosets. Groups of mice (n = 8 – 9) were treated with:
Hayato Yabe, Mohammed Emamussalehin Choudhury, Madoka Kubo, Noriko Nishikawa, Masahiro Nagai, Masahiro Nomoto   +5 more
doaj   +1 more source

Zonisamide improves axial symptoms in dementia with Lewy bodies with parkinsonism: Post hoc analysis of clinical trials

eNeurologicalSci, 2022
Patients with dementia with Lewy bodies (DLB) experience worsening axial symptoms with disease progression, which can negatively affect quality of life.
Yoshio Tsuboi, Kenji Kochi, Hidenori Maruyama, Yuji Matsumoto   +3 more
doaj   +1 more source

The Application of Zonisamide to Patients Suffering from Dementia with Lewy Bodies: Emerging Clinical Data

Drug Design, Development and Therapy, 2021
Babak Tousi,1,2 James B Leverenz2 1Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA; 2Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, OH, USACorrespondence: Babak TousiLou Ruvo Center for ...
Tousi B, Leverenz JB
doaj